Mitoxantron Ebewe (Mitoxantrone)

What Is Mitoxantron Ebewe and What Is It Used For?

Mitoxantrone belongs to a group of medicines known as cytostatic or antineoplastic agents. Within this broader category, it is classified as an anthracenedione, a class of drugs structurally related to the anthracyclines (such as doxorubicin) but with a somewhat different chemical structure designed to reduce certain toxicities. Mitoxantrone works primarily by intercalating into DNA strands, inhibiting the enzyme topoisomerase II, and disrupting both DNA synthesis and DNA repair mechanisms in rapidly proliferating cells. This ultimately leads to cell death in tumor cells and other rapidly dividing cells.

The immunosuppressive properties of mitoxantrone stem from its ability to reduce the proliferation and activity of T cells, B cells, and macrophages. These properties are exploited therapeutically in the management of multiple sclerosis, where aberrant immune system activity attacks the myelin sheath surrounding nerve fibers in the central nervous system. By dampening this immune-mediated damage, mitoxantrone can slow disease progression in carefully selected patients.

Mitoxantrone was first approved for clinical use in the 1980s and has since been included in the World Health Organization's List of Essential Medicines for certain cancer indications. While newer targeted therapies and immunotherapies have become available for many of the cancers mitoxantrone treats, it remains a valuable option in specific clinical scenarios, particularly in resource-limited settings and for patients who cannot tolerate or have failed other treatments.

Approved Indications

Mitoxantron Ebewe is approved for use in the following conditions, each representing a distinct clinical scenario where the drug's mechanism of action provides therapeutic benefit:

• Advanced (metastatic) breast cancer: Used either as monotherapy or in combination with other chemotherapy agents such as cyclophosphamide, 5-fluorouracil, or methotrexate. Mitoxantrone provides an alternative for patients who may not tolerate other anthracycline-based regimens.
• Non-Hodgkin lymphoma (NHL): A type of cancer originating in the lymphatic system. Mitoxantrone can be used as part of various combination chemotherapy protocols for both initial treatment and relapsed disease.
• Acute myeloid leukemia (AML): A cancer of the bone marrow characterized by the overproduction of immature white blood cells. Mitoxantrone is used in induction and consolidation therapy, both as monotherapy in relapsed disease and in combination with other agents such as cytarabine.
• Blast crisis in chronic myeloid leukemia (CML): An advanced phase of CML in which the disease becomes difficult to control. Mitoxantrone is used in combination with other chemotherapy drugs during this phase.
• Advanced castration-resistant prostate cancer: For patients with hormone-refractory prostate cancer experiencing pain, mitoxantrone is administered in combination with corticosteroids (such as prednisone) to provide palliative benefit and pain relief.
• Highly active relapsing multiple sclerosis (MS): Reserved for patients with very active relapsing MS characterized by rapid accumulation of disability, and only when other disease-modifying treatments are unavailable or have proven ineffective. This is a carefully considered use due to the drug's significant toxicity profile.

What Should You Know Before Taking Mitoxantron Ebewe?

Contraindications

There are several absolute contraindications to the use of Mitoxantron Ebewe. The drug must not be administered in the following circumstances, as doing so could result in serious harm or life-threatening reactions:

• Allergy to mitoxantrone: If you have a known hypersensitivity to mitoxantrone or any of the other ingredients in the formulation (listed in the Composition section), you must not receive this medication.
• Sulfite allergy: The formulation contains sodium sulfate. Patients with known sulfite allergy must avoid this product.
• Sulfite-related bronchial asthma: Patients with a form of asthma triggered by sulfite exposure must not use this medication.
• Breastfeeding: Mitoxantrone is excreted in breast milk and can cause serious adverse effects in nursing infants. Breastfeeding must be stopped before treatment begins and must not be resumed until at least one month after the last infusion.
• Pregnancy (for MS treatment): When mitoxantrone is being used specifically for multiple sclerosis, pregnancy is an absolute contraindication. For cancer indications, the decision to use mitoxantrone during pregnancy involves careful risk-benefit assessment, though it should generally be avoided, particularly during the first trimester.

Warnings and Precautions

Before starting treatment with Mitoxantron Ebewe, it is essential that you inform your doctor about all aspects of your medical history. Several conditions and circumstances require special caution, additional monitoring, or may preclude the use of mitoxantrone entirely. Your specialist will carefully evaluate whether the benefits of treatment outweigh the potential risks in your specific situation.

Tell your doctor, pharmacist, or nurse before receiving Mitoxantron Ebewe if you:

• Have liver problems or impaired liver function
• Have kidney problems or impaired kidney function
• Have used mitoxantrone previously (cumulative dose is tracked carefully)
• Have any heart problems, including heart failure, arrhythmia, or coronary artery disease
• Have previously received chest radiation therapy
• Are currently taking medications that affect the heart
• Have previously been treated with anthracyclines or anthracenediones (such as daunorubicin or doxorubicin)
• Have bone marrow problems or are in poor general health
• Have an active infection (infections should be treated before starting mitoxantrone)
• Are planning to receive vaccinations (vaccines may be ineffective during treatment and for 3 months after completion)

Contact your doctor or nurse immediately if you experience any of the following symptoms during treatment:

• Fever, infections, unexplained bleeding or bruising, or unusual weakness or fatigue
• Shortness of breath (including at night), persistent cough, fluid retention (swelling) in ankles or legs, or palpitations (irregular heartbeat) — these cardiac symptoms may occur during treatment or months to years after treatment has ended

Blood Monitoring

Mitoxantrone can significantly affect blood cell counts. Before starting and throughout treatment, regular blood tests will be performed to monitor your blood cells. Your doctor will pay particular attention to the white blood cell count (neutrophils), red blood cell count, and platelet count. More frequent monitoring is required in the following circumstances:

• If your neutrophil count (a type of white blood cell) is below 1,500 cells/mm³
• If you are receiving high doses of mitoxantrone (more than 14 mg/m² per day for 3 days)

Blood count suppression (myelosuppression) typically reaches its lowest point (nadir) approximately 10–14 days after administration, with recovery usually occurring within 21 days. However, if you have received prior chemotherapy or radiation therapy, the bone marrow suppression may be more profound or prolonged.

Cardiac Monitoring

Mitoxantrone can damage the heart muscle and impair cardiac function, potentially leading to congestive heart failure. This risk increases with higher cumulative doses and is greater in patients with pre-existing heart conditions, prior chest radiation, or prior anthracycline exposure. Your doctor will monitor your cardiac function (typically using echocardiography or MUGA scan) before treatment begins and at regular intervals throughout treatment.

For patients receiving mitoxantrone for multiple sclerosis, cardiac monitoring is particularly stringent: heart function must be assessed before treatment initiation, before each subsequent dose, and annually for up to 5 years after the final dose. Treatment should not be initiated if the left ventricular ejection fraction (LVEF) is below the lower limit of normal, and treatment should be discontinued if LVEF falls below 50% or shows a clinically significant decline.

Secondary Malignancies

Mitoxantrone belongs to a group of cancer drugs known as topoisomerase II inhibitors that, when used alone or particularly in combination with other chemotherapy agents and/or radiation therapy, can increase the risk of developing secondary cancers. These include acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), which may develop months to years after treatment. Long-term surveillance is therefore recommended for all patients who have received mitoxantrone.

Pregnancy and Breastfeeding

Mitoxantrone can cause serious harm to an unborn child. Strict contraceptive measures are required for both men and women during treatment:

• Women: Must show a negative pregnancy test before each dose and use effective contraception during treatment and for 8 months after the last dose.
• Men: Must use effective contraception during treatment and for 5 months after the last dose to prevent fathering a child.
• Breastfeeding: Must be discontinued before treatment begins. Breastfeeding must not be resumed until at least one month after the final infusion, as mitoxantrone is excreted in breast milk.

If pregnancy occurs during treatment with mitoxantrone, inform your doctor immediately regardless of whether you are the patient or the partner of the patient.

Fertility

Mitoxantrone may increase the risk of temporary or permanent amenorrhea (absence of menstrual periods) in women of childbearing age. If you are planning to have children in the future, discuss fertility preservation options (such as egg freezing or sperm banking) with your doctor before starting treatment. In male animals, testicular damage and reduced sperm counts have been observed, though human data are limited.

Discoloration Effects

Mitoxantrone can cause a distinctive blue-green discoloration of the urine for up to 24 hours after each infusion. This is a normal pharmacological effect and is not harmful. Patients should be informed of this expected effect to avoid unnecessary concern. Additionally, a bluish discoloration of the whites of the eyes (sclera), skin, and nails may occasionally occur. These effects are temporary and resolve after treatment completion.

Driving and Using Machines

Mitoxantrone may have a minor effect on your ability to drive or operate machinery. Some patients experience side effects such as confusion or fatigue that could impair their ability to safely perform these activities. Do not drive or operate machinery if you experience these effects. You are responsible for assessing whether you are fit to perform these tasks while receiving treatment.

Sodium Content

The 5 ml vial of Mitoxantron Ebewe contains less than 1 mmol (23 mg) of sodium, making it essentially sodium-free. The 10 ml vial contains 34.14 mg of sodium, which corresponds to approximately 1.7% of the WHO recommended maximum daily intake of 2 g sodium for adults. This should be considered for patients on a sodium-restricted diet.

How Does Mitoxantron Ebewe Interact with Other Drugs?

Drug interactions with mitoxantrone can significantly alter its safety profile or reduce the effectiveness of co-administered medications. It is critical that you inform your doctor about all medications you are currently taking, have recently taken, or plan to take, including prescription drugs, over-the-counter medications, and herbal supplements. Your healthcare team will carefully evaluate potential interactions and may adjust doses, change medications, or implement additional monitoring as needed.

You should also inform your doctor if you are already receiving mitoxantrone and are prescribed a new medication that you have not previously taken alongside it, to allow for proper interaction screening before starting the new drug.

Major Interactions

The most clinically significant interactions involve drugs that share overlapping toxicity profiles with mitoxantrone. Combining mitoxantrone with other cardiotoxic drugs, including anthracyclines such as doxorubicin or daunorubicin, substantially increases the risk of irreversible cardiac damage. Cumulative dose limits for cardiac exposure must be carefully tracked when any combination of cardiotoxic agents is used. Similarly, combining mitoxantrone with other myelosuppressive agents can lead to profound and prolonged bone marrow suppression, increasing the risk of life-threatening infections, anemia, and bleeding.

The combination of mitoxantrone with other topoisomerase II inhibitors or radiation therapy carries an increased risk of developing secondary malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These secondary cancers may develop months to years after treatment exposure and require long-term surveillance.

Patients receiving vitamin K antagonists (such as warfarin) for anticoagulation should be aware that mitoxantrone can alter the anticoagulant effect, leading to unpredictable changes in the International Normalized Ratio (INR). More frequent monitoring of INR and appropriate dose adjustments of the anticoagulant are essential during mitoxantrone treatment, particularly in cancer patients.

Minor Interactions

Vaccinations and immunizations may not provide adequate protection during treatment with mitoxantrone and for three months following treatment completion. This is due to the immunosuppressive effects of the drug, which may prevent the immune system from mounting an adequate response to vaccines. Live vaccines should be avoided entirely during this period due to the risk of vaccine-strain infection in an immunocompromised patient. Inactivated vaccines may be administered but may have reduced efficacy.

What Is the Correct Dosage of Mitoxantron Ebewe?

Mitoxantron Ebewe is always administered under the supervision of a specialist physician experienced in the use of cytotoxic chemotherapy. The drug is given as an intravenous infusion (drip) and must always be diluted before administration. Dosing is calculated based on your body surface area (BSA), measured in square meters (m²), which is determined from your height and weight. Regular blood tests are performed throughout treatment, and doses may be adjusted based on the results.

If the infusion fluid leaks from the vein into surrounding tissue (extravasation), the infusion must be stopped immediately and restarted in a different vein. Direct skin, mucous membrane, and eye contact with mitoxantrone must be avoided.

Adults

For adult patients, the dose of Mitoxantron Ebewe is tailored according to the specific cancer being treated, whether the drug is used alone or in combination, and the patient's overall health status and organ function. In monotherapy settings for breast cancer and NHL, the standard starting dose is 14 mg/m² administered as a single intravenous injection, repeatable every 21 days once blood counts have recovered to acceptable levels. Patients with pre-existing bone marrow compromise or poor general condition should receive a reduced starting dose of 12 mg/m² or less.

In combination chemotherapy regimens, the mitoxantrone dose is typically reduced by 2–4 mg/m² compared to monotherapy doses, to account for the additive myelosuppressive effects of the drug combination. For breast cancer, effective combinations include cyclophosphamide and 5-fluorouracil, or methotrexate and mitomycin C. For subsequent treatment cycles, the previous dose can usually be repeated if white blood cell and platelet counts have returned to normal levels within the 21-day interval.

For acute myeloid leukemia in the relapse setting as monotherapy, the recommended induction dose is 12 mg/m²/day given as a single intravenous dose for five consecutive days, resulting in a total course dose of 60 mg/m². In combination regimens, dose adjustments are made based on the degree of myelosuppression and hepatic or renal function.

For blast crisis in CML treated with combination therapy, the recommended dose at relapse is 5–12 mg/m² given daily for 2–4 consecutive days, with a maximum course dose of 48 mg/m².

For castration-resistant prostate cancer, the dose is 12–14 mg/m² given as a short intravenous infusion every 21 days, in combination with low-dose oral corticosteroids such as prednisone.

Multiple Sclerosis Dosing

For multiple sclerosis, mitoxantrone is given under the supervision of a specialist experienced in chemotherapy for MS. The recommended dose is 12 mg/m² administered as a short intravenous infusion (approximately 5 to 15 minutes), which can be repeated every one to three months. The cumulative lifetime dose must not exceed 72 mg/m². Subsequent doses are adjusted based on the degree and duration of myelosuppression observed with prior doses. If repeated courses are given, the dose should be modified according to the severity and duration of blood count suppression.

Elderly Patients

Elderly patients should receive the lowest recommended starting doses due to the increased risk of impaired liver, kidney, or cardiac function, the presence of other medical conditions, and the potential for interactions with concurrent medications. Age-related decline in organ function may affect both the efficacy and safety of mitoxantrone, necessitating careful dose titration and close monitoring throughout treatment.

Children and Adolescents

There is very limited experience with the use of mitoxantrone in children and adolescents. The safety and efficacy of Mitoxantron Ebewe have not been established in patients from birth to 18 years of age. This medication should not be used in pediatric patients unless specifically directed by a specialist as part of a clinical protocol.

What Are the Side Effects of Mitoxantron Ebewe?

Like all medicines, Mitoxantron Ebewe can cause side effects, although not every patient will experience them. The severity and frequency of side effects can vary significantly between patients and depend on factors such as the dose administered, treatment duration, concurrent medications, and the underlying condition being treated. The side effect profiles differ somewhat between cancer patients and MS patients, reflecting differences in dosing regimens and patient populations.

The most serious side effects are cardiotoxicity (heart damage) and myelosuppression (reduced production of blood cells and platelets in the bone marrow). Both require careful monitoring throughout treatment and, in the case of cardiac effects, for years after treatment completion.

Side Effects in Cancer Patients

Side Effects in Multiple Sclerosis Patients

The side effect profile in MS patients shares many features with that seen in cancer patients, though the frequencies may differ due to the generally lower cumulative doses used in MS treatment. The following side effects are particularly noted in the MS population:

How Should You Store Mitoxantron Ebewe?

Mitoxantron Ebewe should be kept out of the sight and reach of children at all times. The medication should not be used after the expiry date stated on the label after "EXP." The expiry date refers to the last day of the stated month. No special storage conditions are required for the unopened concentrate.

The concentrate must be diluted immediately after the vial is first opened. Once diluted, the solution remains stable for 24 hours at room temperature and for a maximum of 3 days when stored at 2–8°C. From a microbiological standpoint, the diluted product should be used immediately. If not used immediately, the in-use storage time and conditions prior to use are the responsibility of the user and should normally not exceed 24 hours at 2–8°C, unless dilution has taken place under controlled, validated aseptic conditions.

Medicines should not be disposed of via household waste or sewage. As a cytotoxic agent, mitoxantrone requires special handling and disposal procedures. Ask your pharmacist about proper disposal of medications that are no longer needed. These measures help to protect the environment and prevent accidental exposure.

What Does Mitoxantron Ebewe Contain?

The active substance in Mitoxantron Ebewe is mitoxantrone, present as mitoxantrone hydrochloride. Each milliliter of the concentrate contains 2 mg of mitoxantrone (as hydrochloride). The vials are available in two sizes: 5 ml vials containing 10 mg of mitoxantrone and 10 ml vials containing 20 mg of mitoxantrone.

Inactive Ingredients (Excipients)

The following inactive ingredients are included in the formulation to ensure stability, appropriate pH, and compatibility with intravenous administration:

• Sodium chloride
• Sodium acetate
• Concentrated acetic acid
• Sodium sulfate
• Hydrochloric acid (for pH adjustment)
• Water for injections

Appearance and Pack Sizes

Mitoxantron Ebewe is a clear, blue solution, free from particles. It is packaged in colorless glass vials within an outer carton. Available pack sizes include: 1×5 ml, 5×5 ml, 10×5 ml, 1×10 ml, 5×10 ml, and 10×10 ml. Not all pack sizes may be marketed in every country.

Sodium Content

The 5 ml vial contains less than 1 mmol (23 mg) of sodium per vial, meaning it is essentially "sodium-free." The 10 ml vial contains 34.14 mg of sodium per vial, equivalent to 1.7% of the WHO recommended maximum daily sodium intake for adults (2 g/day). This information is relevant for patients on sodium-restricted diets or those requiring multiple vials per treatment course.

Manufacturer

Mitoxantron Ebewe is manufactured by EBEWE Pharma Ges.m.b.H. Nfg. KG or Fareva Unterach GmbH, located at Mondseestrasse 11, 4866 Unterach, Austria. The marketing authorization is held by EBEWE Pharma.